Skip to Main Content

Print | Bookmark | Email | Font Size: + |

May 11, 2021

Technical Assessment

To determine compliance with a policy, a Technical Assessment (TA) is required for molecular assays that are laboratory developed tests (LDT). During the TA period, developers should suspend claims submission for the test service. Before submitting a TA, labs must register a test and obtain a unique identifier through the DEX® Diagnostics ExchangeExternal Website.

To receive favorable review results, the assay must demonstrate clinical utility (CU), fulfill the CMS "reasonable and necessary" criteria, and meet analytical and clinical validity (AV/CV) standards. In addition to these categories of evidence, CMS has directed MolDX to follow the ACCE criteria developed by the Centers for Disease Control and Prevention. For more information on the ACCE model, vie cdc.gov/ACCEExternal Website.

To reduce delays and unfavorable determinations, please ensure that the TA submission is complete. See the Technical Assessment Submission ChecklistExternal Website for specific instructions on how to submit all required documentation for a TA.

Send Technical Assessments to MolDX@PalmettoGBA.com.

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved